Dublin, April 05, 2023 (GLOBE NEWSWIRE) -- The "Multiple System Atrophy (MSA) - Market Insight, Epidemiology And Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.

Dublin, May 07, 2025 (GLOBE NEWSWIRE) -- The "Multiple System Atrophy (MSA) Market - A Global and Regional Analysis: Focus on Country and Regional Analysis - Analysis and Forecast, 2025-2035" report ...

– Company is advancing ATH434 in late-stage clinical development for Multiple System Atrophy, a rapidly progressive neurodegenerative disease with no approved therapies – MSA is a progressive ...

Emrusolmin is expected to improve symptoms of MSA by targeting alpha synuclein oligomers. The Food and Drug Administration (FDA) has granted Fast Track designation to emrusolmin (TEV-56286) for the ...

In a study published in Neuron, researchers have identified four new genetic risk factors for multiple system atrophy (MSA), shedding light on this poorly understood disorder. The study, which ...

The Multiple System Atrophy Coalition was founded in 1989 as a Support Group offering a toll-free hotline and an annual patient/caregiver conference. The new name was chosen to better reflect the ...

There is currently no cure for the rare neurodegenerative disorder multiple system atrophy (MSA), and its rarity has made it difficult to understand how the disease progresses. Now a research team has ...

Currently no disease-modifying or neuroprotective treatments exist for MSA, nor are there effective medications to treat the cerebellar ataxia in MSA-C or the parkinsonian features in MSA-P. Physical ...

NEW HAVEN, Conn., Sept. 27, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced results from a focused analysis of a clinical trial of verdiperstat in ...